Snowflake Inc. (NYSE:SNOW – Get Free Report) Director Mark Garrett sold 100,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $250.00, for a total value of $25,000,000.00. Following the completion of the sale, the director directly owned 8,801 shares in the company, valued at $2,200,250. This trade represents a 91.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Snowflake Trading Down 7.4%
Shares of SNOW stock opened at $241.88 on Thursday. Snowflake Inc. has a fifty-two week low of $118.30 and a fifty-two week high of $284.99. The company has a quick ratio of 1.30, a current ratio of 1.05 and a debt-to-equity ratio of 1.18. The business has a fifty day simple moving average of $162.02 and a 200-day simple moving average of $190.30. The stock has a market cap of $83.62 billion, a P/E ratio of -68.72 and a beta of 1.35.
Snowflake (NYSE:SNOW – Get Free Report) last issued its quarterly earnings data on Wednesday, May 27th. The company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.07. Snowflake had a negative net margin of 23.79% and a negative return on equity of 50.50%. The firm had revenue of $1.39 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the prior year, the company earned $0.24 EPS. The firm’s revenue was up 33.5% on a year-over-year basis. On average, analysts forecast that Snowflake Inc. will post -2.15 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on SNOW
Institutional Investors Weigh In On Snowflake
Hedge funds and other institutional investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new position in Snowflake in the fourth quarter valued at $28,000. Greenline Wealth Management LLC purchased a new stake in Snowflake in the 4th quarter valued at about $29,000. GoalVest Advisory LLC increased its stake in shares of Snowflake by 221.4% during the 4th quarter. GoalVest Advisory LLC now owns 135 shares of the company’s stock valued at $30,000 after acquiring an additional 93 shares during the last quarter. Physician Wealth Advisors Inc. increased its stake in shares of Snowflake by 56.0% during the 4th quarter. Physician Wealth Advisors Inc. now owns 142 shares of the company’s stock valued at $31,000 after acquiring an additional 51 shares during the last quarter. Finally, Emerald Advisers LLC lifted its holdings in shares of Snowflake by 95.2% during the 1st quarter. Emerald Advisers LLC now owns 205 shares of the company’s stock worth $31,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 65.10% of the company’s stock.
Snowflake News Roundup
Here are the key news stories impacting Snowflake this week:
- Positive Sentiment: Snowflake used its Summit 26 event to showcase major AI product launches and governance upgrades, including Horizon Context, CoWork enhancements, and Datastream, reinforcing its position as a platform for production-grade enterprise AI. Snowflake Summit 26 Puts Governed Enterprise AI At Center Stage
- Positive Sentiment: Snowflake announced deeper partnerships and ecosystem integrations with Anthropic, Cognizant, Collibra, Ataccama, RelationalAI, ThoughtSpot, and others, suggesting growing enterprise adoption of its AI data cloud. Snowflake and Anthropic Accelerate Enterprise AI Adoption Driven by Rising Demand for Governed AI
- Positive Sentiment: Multiple analysts raised targets or reiterated bullish ratings, including UBS, Piper Sandler, Needham, BTIG, TD Cowen, and Scotiabank, which can support the stock by signaling stronger long-term revenue and earnings expectations.
- Positive Sentiment: Customer and partner announcements from companies like Sanofi, Thomson Reuters, TransUnion, NIQ, and Blue Yonder highlight real-world use cases for Snowflake’s AI and governance tools, strengthening the investment case around monetization. Sanofi Chooses Snowflake to Accelerate its AI-Powered Drug Development
- Neutral Sentiment: Several partner award and marketplace launch announcements at Summit 26 add to the narrative of expanding ecosystem momentum, but they are less likely than product launches or analyst upgrades to move the stock on their own.
- Negative Sentiment: Insider selling by directors Frank Slootman and Mark Garrett may create a modest overhang, even though the sales were disclosed and at least one was tied to a pre-arranged trading plan.
About Snowflake
Snowflake Inc is a cloud-native data platform company that provides a suite of services for storing, processing and analyzing large volumes of data. Its core offering, often described as the Snowflake Data Cloud, combines data warehousing, data lake and data sharing capabilities in a single managed service delivered across major public cloud providers. The platform is designed to support analytics, data engineering, data science and application workloads with a focus on scalability, concurrency and simplified administration.
Key products and capabilities include a multi-cluster, shared-data architecture that separates compute from storage; continuous data ingestion and streaming; support for structured and semi-structured data formats; tools for data governance, security and compliance; and developer frameworks for building data applications.
See Also
- Five stocks we like better than Snowflake
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Receive News & Ratings for Snowflake Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Snowflake and related companies with MarketBeat.com's FREE daily email newsletter.
